Intelligent Adaptive Subcutaneous Medical Implant System

Publication ID: 24-11857671_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Intelligent Adaptive Subcutaneous Medical Implant System,” Published Technical Disclosure No. 24-11857671_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857671_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,671.

Summary of the Inventive Concept

An advanced subcutaneous medical implant system that dynamically adjusts drug delivery rates in response to a patient's changing physiological conditions, ensuring personalized and optimal treatment outcomes.

Background and Problem Solved

The original medical implant patent addressed the issue of initial drug 'burst' in existing drug implants. However, the new inventive concept tackles the limitation of static drug delivery rates in current implants, which may not be effective for patients with varying physiological conditions. This new concept provides a solution to this problem by incorporating adaptive drug release properties and machine learning algorithms to optimize treatment.

Detailed Description of the Inventive Concept

The intelligent adaptive subcutaneous medical implant system comprises a matrix with adaptive drug release properties, which can adjust drug delivery rates in response to changes in a patient's physiological conditions. The system includes a wearable device that uses artificial intelligence to predict and prevent adverse drug reactions. The implant is designed to learn a patient's drug response patterns and adapt its drug release accordingly. The modular design allows for interchangeable drug cartridges, each releasing a specific drug or combination of drugs in a controlled manner. The biodegradable matrix degrades at a predetermined rate, releasing therapeutic agents in a sustained and controlled manner.

Novelty and Inventive Step

The new claims introduce a paradigm shift in subcutaneous medical implants by incorporating adaptive drug release properties, machine learning algorithms, and wearable devices. These advancements provide a significant improvement over the original patent, enabling personalized and optimal treatment outcomes.

Alternative Embodiments and Variations

Alternative embodiments of the intelligent adaptive subcutaneous medical implant system could include variations in the matrix composition, wearable device design, and artificial intelligence algorithms. For example, the matrix could be designed to respond to specific biomarkers or the wearable device could be integrated with other health monitoring systems.

Potential Commercial Applications and Market

The intelligent adaptive subcutaneous medical implant system has significant commercial potential in the pharmaceutical and medical device industries, particularly in the areas of personalized medicine and precision healthcare. The system's ability to adapt to individual patients' needs could lead to improved treatment outcomes, reduced healthcare costs, and increased patient satisfaction.

CPC Classifications

SectionClassGroup
A A61 A61K9/0024
A A61 A61K31/4468
A A61 A61K31/485
A A61 A61K45/06

Field of Art

Medical device engineering, specifically subcutaneous drug delivery implant systems, requiring expertise in biomaterials, pharmaceutical formulation, controlled drug release mechanisms, and biomedical device design

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or pharmaceutical scientist with advanced degree, experience in drug delivery systems, knowledge of materials science, understanding of controlled release technologies, and familiarity with implantable medical device design principles

Obviousness Rationale

A PHOSITA would recognize that the PTD's adaptive drug delivery system represents a predictable extension of the source patent's non-homogenous drug matrix concept. The fundamental innovation of controlling drug release through matrix composition is preserved, with the PTD introducing machine learning and responsive technologies as natural technological progressions. These variations represent incremental improvements using known techniques in drug delivery and biomedical engineering.

Obvious Combinations & Variations

Source Patent Element
Non-homogenous matrix with multiple drug materials for controlled delivery
PTD Variation
Adaptive matrix with AI-driven drug release responsive to physiological conditions
Obviousness Reasoning
Predictable application of machine learning to existing controlled release technologies, representing a known technique for optimizing drug delivery systems
Source Patent Element
Implantable device with coating for drug delivery modulation
PTD Variation
Modular implant with interchangeable drug cartridges and wearable monitoring device
Obviousness Reasoning
Logical extension of existing implant design principles, utilizing known modular medical device design approaches
Source Patent Element
Method of reducing initial drug delivery burst
PTD Variation
Personalized drug delivery learning system that adapts to individual patient responses
Obviousness Reasoning
Natural progression of drug delivery optimization techniques, applying machine learning to solve known variability challenges in therapeutic treatments
Source Patent Element
Subcutaneous implant with controlled drug release matrix
PTD Variation
Biodegradable matrix with predetermined degradation rate for sustained therapeutic agent release
Obviousness Reasoning
Application of known biodegradable material technologies to existing controlled release implant designs
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857671 and the disclosed variations, a person having ordinary skill in the art would find the claimed innovations of the presented technical disclosure obvious and anticipated, specifically rendering obvious any patent claims involving adaptive, personalized drug delivery implant systems with machine learning-enabled response mechanisms.

Original Patent Information

Patent NumberUS 11,857,671
TitleMedical implant